KR20240056926A - Composition for enhancing immunity and preventing, ameliorating or treating inflammatory bowel disease comprising Fritillaria thunbergii extract as effective component - Google Patents

Abstract

The present invention relates to a composition for improving immunity and preventing, ameliorating or treating inflammatory bowel disease, which contains extract of snail hair as an active ingredient. The extract of snail hair is administered to an animal model of inflammatory bowel disease induced by dextran sulfate sodium (DSS). When administered, weight loss and shortening of colon length caused by DSS administration are suppressed, and treatment of mouse macrophages with the cut hair extract and its crude polysaccharide fraction results in macrophage proliferation and production of NO and cytokines (TNF-α and IL-6). Since this increases, it can be very useful in health functional foods or medicines for improving immunity and preventing, improving or treating inflammatory bowel disease.

Description

Composition for enhancing immunity and preventing, ameliorating or treating inflammatory bowel disease comprising Fritillaria thunbergii extract as effective component}

The present invention relates to a composition for improving immunity and preventing, improving, or treating inflammatory bowel disease, comprising an extract of jaundice as an active ingredient.

The immune system can be divided into natural resistance, non-specific immune system, and specific immune system. Natural resistance (first line of defense) refers to anatomical and physiological elements that block all invaders, including microorganisms, regardless of their type, and non-specific immunity (second line of defense) refers to phagocytes that eliminate invaders that break through natural resistance and enter the body. The specific defense system (third line of defense) refers to an immune system composed of lymphocytes. Among these, the specific immune system is a highly developed immune system with memory and the ability to distinguish between self and non-self. In addition, white blood cells form the second or third line of defense and take charge of foreign substances that have broken through the first line of defense and entered the body. In case of bacterial or viral infection or inflammatory response, the regulation of macrophage and lymphocyte activity determines the therapeutic effect of the medicine. plays a central role in

Macrophages are cells with various functions and play an important role in the immune system by producing various cytokines and nitric oxide (NO) in oxidative stress situations. In particular, iNOS (inducible nitric oxide synthase), which is expressed in macrophages by stimuli such as lipopolysaccharide (LPS), cytokines, and TNF-α, is known to produce large amounts of NO for a long time and promote NFκB activity. . Reactive oxygen species (ROS) such as superoxide anion (O ₂ ^- ), hydrogen peroxide (H ₂ O ₂ ), and nitric oxide (NO) by activated macrophages. Production is an important cytotoxic and cell activity inhibition mechanism in non-specific immunity. Therefore, various studies are being conducted on the correlation between safe natural compounds and the production of ROS and NO in macrophages.

Meanwhile, inflammatory bowel disease (IBD) is a disease that includes ulcerative colitis, Crohn's disease, or Behcet's disease. Activation of inflammatory cells is known to be an important etiology, and activation of inflammatory cells with anti-inflammatory drugs, immunosuppressants, etc. Treatment through suppression is necessary. In other words, even if it is an intestinal disease, the treatment method must be different depending on the specific etiology, etc. In particular, in the case of inflammatory bowel disease, the most important factor in treating the disease is the preparation of measures to suppress and alleviate inflammation-related symptoms. Persistent or inappropriate activation of the intestinal immune system plays an important role in the pathophysiology of chronic mucosal inflammation, especially through infiltration of neutrophils, macrophages, lymphocytes, and mast cells, ultimately leading to mucosal destruction and ulceration.

In inflammatory bowel disease, various inflammatory cytokines are secreted from the intestinal mucosa. TNF-α is highly expressed in the colonic lumen and colonic epithelial cells of patients with ulcerative colitis, and recent studies have shown that TNF-α plays an important role in the pathogenesis of ulcerative colitis. Infliximab, an anti-TNF-α antibody, is known to be effective not only in the treatment of boils but also in the treatment of previously untreated Crohn's disease, but this treatment is expensive, and in some patients, it can cause fluid reactions or infectious complications. The same side effects occur. Currently, inflammatory bowel disease treatments include 5-aminosalicylic acid (5-ASA) drugs that block the production of prostaglandins, such as sulfasalazine, or steroid-type immunosuppressants. . Sulfasalazine is prone to side effects or adverse effects such as abdominal fullness, headache, rash, liver disease, leukopenia, agranulocytosis, and male infertility.

Meanwhile, Fritillariae Thunbergii Bulbs is a perennial herb that grows naturally in the mountainous meadows of the northern part of Korea, Gapsan in South Hamgyong Province, and Mt. Baekdu. The height is about 25cm, the peduncle is white, consists of 5 to 6 fleshy scales, and is round with a whisker root at the bottom. The main stem grows straight, and the leaves are opposite or whorled in groups of three, linear, 10 cm long, without petioles, with sharp ends, and the upper leaves are curled like tendrils.

As prior art related to immune enhancement or inflammatory bowel disease, Korea Patent Publication No. 2022-0108739 discloses a composition for improving, alleviating, preventing or treating inflammatory bowel disease containing extract of sine, and Korean Patent No. 1536652 discloses turmeric. Although a composition for enhancing immunity containing the extract has been disclosed, there has been no disclosure at all regarding a composition for enhancing immunity and preventing, improving, or treating inflammatory bowel disease containing the extract of the Japanese herbal medicine of the present invention as an active ingredient.

The present invention was developed in response to the above-mentioned needs, and provides a composition for improving immunity and preventing, improving, or treating inflammatory bowel disease, which contains an extract of dextran sulfate sodium (DSS) as an active ingredient. When administered with the extract of the shellfish extract in an animal model of intestinal disease, weight loss and shortening of the colon length caused by DSS administration are suppressed, and treatment with the extract and its crude polysaccharide fraction in mouse macrophages results in macrophage proliferation, NO, and cytokines. The present invention was completed by confirming the immune-enhancing effect through increased production of (TNF-α and IL-6).

In order to solve the above problems, the present invention provides an immune booster containing Fritillaria thunbergii extract or a crude polysaccharide fraction thereof as an active ingredient; and a health functional food composition for preventing or improving inflammatory bowel disease.

Additionally, the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease containing an extract of Fritillaria thunbergii or a crude polysaccharide fraction thereof as an active ingredient.

In addition, the present invention provides an immune-enhancing device containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and feed additives for preventing or improving inflammatory bowel disease.

In addition, the present invention provides an immune-enhancing device containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and a veterinary composition for preventing or treating inflammatory bowel disease.

The present invention relates to a composition for improving immunity and preventing, ameliorating or treating inflammatory bowel disease, which contains extract of snail hair as an active ingredient. The extract of snail hair is administered to an animal model of inflammatory bowel disease induced by dextran sulfate sodium (DSS). When administered, weight loss and colon length shortening caused by DSS administration are suppressed, and treatment of mouse macrophages with the cut hair extract and its crude polysaccharide fraction results in macrophage proliferation and production of NO and cytokines (TNF-α and IL-6). This increase has an immune-boosting effect.

Figure 1 shows the inhibitory effect on weight loss (A) and colon length shortening (B) caused by DSS administration when the dextran sulfate sodium (DSS)-induced inflammatory bowel disease mouse model was treated with the extract of the present invention. It is shown. ## indicates a statistically significant decrease in the colon length of the negative control group compared to the normal group, meaning p < 0.01, * and ** indicate the group treated with hot water extract of the cuttlefish extract, the group administered with the ethanol extract of the cuttlefish plant, or the positive control group compared to the negative control group. This means that the colon length increased statistically significantly, * means p<0.05, and ** means p<0.01.
Figure 2 shows the inhibitory effect on the increase in mesenteric lymph node weight (A) and spleen weight (B) by DSS administration when the inflammatory bowel disease mouse model induced by DSS (dextran sulfate sodium) was treated with the extract of the present invention. It is shown. ## indicates a statistically significant increase in the weight of the mesenteric lymph nodes and spleen in the negative control group compared to the normal group, meaning p<0.01, and * means the group treated with hot-water extract of the antler root, the group administered the ethanol extract of the angiosperm root compared to the negative control group, or the positive group. The weight of the mesenteric lymph nodes or spleen in the control group was statistically significantly reduced, meaning p<0.05.
Figure 3 shows the results of confirming the Raw 264.7 cell survival rate when the cut-out hair extract and its crude polysaccharide fraction of the present invention were treated at different concentrations. * and ** indicate a statistically significant increase in cell viability in the group treated with the cuttlefish extract of the present invention or its crude polysaccharide fraction at the corresponding concentration compared to the untreated group, * is p < 0.05, * * means p<0.01.
Figure 4 shows the analysis results of NO (Nitric oxide) production when the extract of the present invention and its crude polysaccharide fraction were treated at different concentrations. Normal is a group in which nothing was processed, and LPS is a group in which LPS was processed.
Figure 5 shows the results of analysis of the production of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) when the extract of the present invention and its crude polysaccharide fraction were treated at different concentrations. Normal is a group in which nothing was processed, and LPS is a group in which LPS was processed.

In order to achieve the object of the present invention, the present invention provides an immune-enhancing device containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and a health functional food composition for preventing or improving inflammatory bowel disease.

The cut hair extract can be prepared by a method comprising the following steps, but is not limited to this:

(1) Extracting by adding an extraction solvent to the broken hair;

(2) filtering the extract of step (1); and

(3) Concentrating and drying the filtered extract of step (2) to prepare an extract.

In step (1), the extraction solvent is preferably selected from water, C ₁ -C ₄ lower alcohol, or a mixture thereof, more preferably water or ethanol, but is not limited thereto.

In the above manufacturing method, all conventional methods known in the art can be used as the extraction method, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. The extraction solvent is preferably added in an amount of 1 to 20 times the weight of the broken hair for extraction, and more preferably, it is added in an amount of 5 to 15 times. The extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, but is not limited to this. In the above method, the vacuum concentration in step (3) is preferably performed using a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, drying is preferably performed by reduced pressure drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.

The crude polysaccharide fraction of the cut-off hair extract of the present invention may be a fraction obtained by fractionating a hot-water extract of cut-throat hair extract through a non-heat treatment process or a fraction obtained by precipitation in an organic solvent such as ethanol, but is not limited thereto.

The composition is preferably manufactured in a dosage form selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.

When using the health functional food composition of the present invention as a food additive, the cuttlefish extract can be added as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention or improvement). Generally, when producing a food or beverage, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw materials. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There are no special restrictions on the types of foods above. Examples of foods to which the extract can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, These include alcoholic beverages and vitamin complexes, and include all health functional foods in the conventional sense.

When the composition of the present invention is used as a health drink, it may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional drinks. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumarin and stevia extract or synthetic sweeteners such as saccharin or aspartame can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 g of the composition of the present invention. The composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal neutralizer, pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonic acid. It may contain carbonating agents used in beverages. Additionally, the composition of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

Additionally, the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease containing an extract of Fritillaria thunbergii or a crude polysaccharide fraction thereof as an active ingredient.

The inflammatory bowel disease may preferably be ulcerative colitis, Crohn's disease, or Behcet's disease, but is not limited thereto.

The composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents in addition to the above active ingredients, and may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include capsules, powders, granules, tablets, pills, etc. These solid preparations contain one or more compounds and at least one excipient, such as starch, calcium carbonate, sucrose, or lactose ( It is prepared by mixing lactose, gelatin, etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate, talc, etc. are also used. Liquid preparations for oral administration include suspensions, emulsions, syrups, aerosols, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspension solvents may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurel, glycero gelatin, etc. can be used. When administering parenterally, it is preferable to choose external dermal application or intraperitoneal, rectal, intravenous, intramuscular, subcutaneous, intrauterine dura, or intracerebrovascular injection.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat the disease with a reasonable benefit/risk ratio applicable to medical treatment, and the level of the effective amount is determined by the type, severity, and activity of the patient's disease. , can be determined based on factors including sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or multiple times. Considering all of the above factors, it is important to administer an amount that can achieve maximum effect with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

The dosage of the composition of the present invention varies depending on the patient's weight, age, gender, health condition, diet, administration time, administration method, excretion rate, and severity of disease. The composition of the present invention can be used alone or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, and methods using biological response modifiers.

In addition, the present invention provides an immune-enhancing device containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and feed additives for preventing or improving inflammatory bowel disease.

The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals. The type of feed is not particularly limited, and feed commonly used in the art can be used. Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products; Examples include animal feeds such as proteins, inorganic substances, fats and oils, minerals, fats and oils, single-cell proteins, zooplanktons or food. These may be used alone or in combination of two or more types.

In addition, the present invention provides an immune-enhancing device containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and a veterinary composition for preventing or treating inflammatory bowel disease.

The veterinary composition containing the cut hair extract of the present invention may further include appropriate excipients and diluents according to conventional methods. Excipients and diluents that may be included in the veterinary composition containing the extract of snail hair of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, and gelatin. , calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid. Examples include paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.

The veterinary composition containing the cut hair extract according to the present invention may further include fillers, anti-coagulants, lubricants, wetting agents, spices, emulsifiers, preservatives, etc. The veterinary composition according to the present invention is administered to an animal after being administered. Can be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient, and the dosage form can be powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, It may be in the form of soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile external preparations, etc.

The veterinary composition according to the present invention may vary depending on the age, sex, and weight of the animal, but can be administered once or several times a day, and the dosage increases or decreases depending on the route of administration, degree of disease, sex, weight, age, etc. It can be. Accordingly, the above dosage does not limit the scope of the present invention in any way.

Hereinafter, the present invention will be described in detail through examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited to the following examples.

<Materials and Methods>

1. Animal rearing conditions

A 6-week-old male mouse (C57BL/6) was purchased from Duyeol Biotech and used in the experiment after being acclimatized for one week. During the adaptation period, the general condition was observed and healthy mice were used in the experiment. During the test period, the experimental animals were kept in polycarbonate cages, and were fed ad libitum AIN-93G (Duyeol Biotech, Seoul), a mouse-specific feed. Negative water was freely supplied with reverse osmosis (RO) water.

2. Animal testing to induce inflammatory bowel disease

To induce inflammatory bowel disease in mice, 2.5% (w/v) dextran sodium sulfate (DSS, MP Biomedicals) drinking water was prepared. The experimental group was divided into a normal group, a negative control group, a positive control group (mesalazine, 200 mg/kg), a group administered with a hot water extract of the snail root (100 mg/kg), and a group administered with an ethanol extract from the snail root (100 mg/kg). Sample administration was conducted It was administered orally using a mouse pad. The experimental group, excluding the normal group, was freely fed 2.5% DSS drinking water for 8 days and then replaced with normal drinking water for 5 days, and the samples were administered daily for 13 days. On the last day of sample administration, mice were sacrificed to analyze the improvement effect on inflammatory bowel disease.

3. Efficacy test to improve inflammatory bowel disease

During the test period, the body weight of each experimental group was measured every day. After sacrificing the mice, the colon tissue, mesenteric lymph nodes, and spleen of each experimental group were removed and the length of the colon, mesenteric lymph nodes, and spleen weight were measured and analyzed.

4. Cell viability analysis

RAW 264.7 cells, a macrophage cell line, were distributed in a 96-well plate at a concentration of 2 × 10 ⁴ cells/well, and then the hair extract of the present invention was added at different concentrations (0.23, 0.69, 2.06, 6.17, 18.5, 55.6, 167, and 500). ㎍/㎖) and cultured for 24 hours at 37°C and 5% CO ₂ conditions. CCK-8 assay was performed on cells after culture. Afterwards, the absorbance at 450 nm was measured using an ELISA reader (BioTek Instruments, Winooski, VT), and the relative cell viability (% of control) was calculated by comparison with the control group.

5. NO (Nitric oxide) production analysis

RAW 264.7 cells were distributed in a 96-well culture plate at ² , 18.5, 55.6, 167, and 500㎍/㎖) and cultured for 24 hours. After 24 hours of incubation, each cell culture was separated, and 540 cells were grown using a 1:1 Griess reagent mixture (0.1% N-1-napthylethylenediamine dihydrochloride diluted in sterile water, 1% sulfanilamide in 5% phosphoric acid). Absorbance was measured at ㎚ and changes in NO production were analyzed.

6. Cytokine production analysis

RAW 264.7 cells were distributed in a 96-well culture plate at ² , 18.5, 55.6, 167, and 500㎍/㎖) respectively. After 24 hours of incubation, the production of TNF-α and IL-6 was measured by absorbance at 450 nm using an enzyme-linked immunosorbent assay (ELISA, Quantikine ELISA Kit, R&D system, USA).

7. Statistical processing

The data obtained in the present invention were expressed as mean ± standard error, and statistical analysis was calculated by one-way analysis of variance accompanied by Dunnett's test.

Preparation Example 1. Preparation of cut-off hair extract

(1) Cut-throat moss thermal water extract

500 g of cut hair was placed in 3.5 liters of distilled water, refluxed (heating mantle) for 3 hours, filtered through qualitative filter paper (ϕ185mm), and freeze-dried to obtain a hot water extract of cut hair.

(2) Ethanol extract of cuttlefish hair

500 g of cut hair was placed in 3.5 liters of 70% (v/v) ethanol, extracted under reflux (heating mantle) for 3 hours, filtered and soaked with Qualitative Filter Paper (ϕ185mm), and then concentrated with a rotary evaporator. Then it was freeze-dried.

(3) Crude polysaccharide fraction of cuttlefish

1 g of the above-prepared hot water extract of Jeolpaemo was dissolved in 10 ml of water, stirred and extracted for 1 hour, then 30 ml of ethanol was added, precipitated for 24 hours, centrifuged at 2,000 rpm for 30 minutes at 4°C, and separated into supernatant and residue. The remaining residue was freeze-dried at -70°C to obtain a crude polysaccharide fraction of cut hair.

Example 1. Confirmation of inflammatory bowel disease improvement efficacy of cuttlefish extract

In order to confirm the effect of the spore hair extract on improving inflammatory bowel disease in an animal model, the sage hair extract was orally administered to C57BL/6 mice for 13 days. At the start of the test, 2.5% DSS water was freely fed for 8 days, and the mice remained normal for 5 days. After inducing inflammatory bowel disease by replacing drinking water, the mice were sacrificed. In an inflammatory bowel disease animal model, changes in mouse body weight, colon length, mesenteric lymph nodes, and spleen weight were observed.

As a result, as shown in Figure 1, there was a statistically significant decrease in body weight in the negative control group fed only DSS compared to the normal group. In contrast, in the group administered the cuttlefish extract of the present invention, the body weight reduced by DSS administration was It was confirmed that the increased and shortened colon length increased statistically significantly.

In addition, it was confirmed that the weight of the mesenteric lymph nodes and spleen, which were increased due to DSS administration, was statistically significantly reduced due to the administration of spleen hair extract (Figure 2).

Example 2. Confirmation of immune-enhancing efficacy of cuttlefish extract and its crude polysaccharide fraction

(1) Cell viability

To verify the immune-boosting effect of the cuttlefish extract and its crude polysaccharide fraction, changes in cell proliferation were observed in RAW 264.7 cells.

As a result, as shown in Figure 3, the proliferation of macrophages was increased in a concentration-dependent manner in each experimental group treated with the cut-out hair extract and its crude polysaccharide fraction compared to the untreated group.

(2) NO and cytokines (TNF-α and IL-6)

It was confirmed that the production of NO and cytokines (TNF-α and IL-6) was increased due to treatment with the cut-out hair extract and its crude polysaccharide fraction (Figures 4 and 5), through which the cut-out hair extract and its crude oil of the present invention were confirmed to be increased. It was found that the polysaccharide fraction has an immune-enhancing effect.

Claims (8)

Immunity enhancement containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and health functional food compositions for preventing or improving inflammatory bowel disease. The method of claim 1, wherein the extract is an immune booster, characterized in that it is extracted using water, a lower alcohol of C ₁ to C ₄ , or a mixture thereof; and health functional food compositions for preventing or improving inflammatory bowel disease. The method of claim 1, wherein the composition is manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage; and health functional food compositions for preventing or improving inflammatory bowel disease. A pharmaceutical composition for the prevention or treatment of inflammatory bowel disease containing an extract of Fritillaria thunbergii or a crude polysaccharide fraction thereof as an active ingredient. The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 4, wherein the inflammatory bowel disease is ulcerative colitis, Crohn's disease, or Behcet's disease. The pharmaceutical composition for preventing or treating inflammatory bowel disease according to claim 4, further comprising a pharmaceutically acceptable carrier, excipient, or diluent in addition to the active ingredient. Immunity enhancement containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and feed additives for preventing or improving inflammatory bowel disease. Immunity enhancement containing Fritillaria thunbergii extract or its crude polysaccharide fraction as an active ingredient; and veterinary compositions for preventing or treating inflammatory bowel disease.